Take Action Now for Essential Tremor |
|
Donate
Resources >Essential TremorPatient AdvocacyNewslettersET Treatment |
collaboration >Who we areLeadershiPPartnershipsDiann Shaddox's Story |
Participate >ResearchET Talks webinarET Champions Support GroupNational ET Conference |
|
|
The Diann Shaddox Foundation is leading the way to find new therapies and a cure for Essential Tremor.
Grassroots advocacy serves as the backbone of our efforts and our foundation. By joining forces, we can effectively influence legislation and policy decisions to enhance the quality of life for everyone affected by ET.
Your involvement can help elevate unheard voices and prioritize the ET community's needs. We need the world to understand that Essential Tremor is more than just tremors. With your help, we can find a cure and make a difference!
"We recognize the significance of this responsibility, and I want everyone to feel assured that we are actively working to get this done. No one knows Essential Tremor better than someone who lives with it."
Diann Shaddox, Founder, lives with ET.
|
Updates
|
The latest Updates from the Foundation
|
Ask the MD
ET Talks Saturday, 2025 Register >>> Time: 2:00 pm ET Duration: 1 hr.
Register Now >>> ET Worldwide FB Group Join Now >>>
|
In the News
Stress Through the Holidays The holidays are a time for family and cheer, but making sure the house is clean, the food is ready, and the presents are wrapped and ready to be opened can be overwhelming. These factors can bring unwanted stress and depression in a time meant for happiness. Learn More >>> 
Giving Tuesday
Turn today’s dreams into tomorrow’s realities. Please lead the way by contributing to our Giving Tuesday fund early! By joining forces, your generous gift to the Diann Shaddox Foundation is crucial for advancing vital research and developing data systems that bring us closer to a cure for Essential Tremor. Together, we can bring hope to those who need it most. Please help by donating today! Learn More >>> |
Exciting News!!!!
Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
“To all the patients living with ET, I am thrilled with the results of the Essential3 Program. All of us at Praxis will be forever indebted to the bravery you have demonstrated participating in the program, in the face of such a debilitating condition,” said Marcio Souza, president and chief executive officer. “Patients in Essential3 had been living with essential tremor for an average of 30 years, with worsening symptoms and no effective treatment options. In just 15 months of recruitment, we had over 200,000 people interested in participating in this study, which is a powerful reflection of the large unmet need for a therapy like ulixacaltamide. We look forward to the opportunity to have a pre-NDA meeting with the FDA soon to discuss the potential NDA.”
“This is incredibly exciting news, for the first time we have a medication designed specifically for our ET patients. As a clinical researcher and movement disorder specialist, it is very rewarding to see such positive results with the potential to truly change lives. Ulixacaltamide represents more than data on a chart - it is a real opportunity to help people regain their independence and improve their daily functioning in meaningful ways,” said Salima Brillman, MD, Founder, Parkinson's Disease and Movement Disorders Center of Silicon Valley, co-lead investigator of the E3 program.
BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced positive topline results for the Phase 3 Essential3 program of ulixacaltamide in essential tremor (ET)
Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
“To all the patients living with ET, I am thrilled with the results of the Essential3 Program. All of us at Praxis will be forever indebted to the bravery you have demonstrated participating in the program, in the face of such a debilitating condition,” said Marcio Souza, president and chief executive officer. “Patients in Essential3 had been living with essential tremor for an average of 30 years, with worsening symptoms and no effective treatment options. In just 15 months of recruitment, we had over 200,000 people interested in participating in this study, which is a powerful reflection of the large unmet need for a therapy like ulixacaltamide. We look forward to the opportunity to have a pre-NDA meeting with the FDA soon to discuss the potential NDA.”
“This is incredibly exciting news, for the first time we have a medication designed specifically for our ET patients. As a clinical researcher and movement disorder specialist, it is very rewarding to see such positive results with the potential to truly change lives. Ulixacaltamide represents more than data on a chart - it is a real opportunity to help people regain their independence and improve their daily functioning in meaningful ways,” said Salima Brillman, MD, Founder, Parkinson's Disease and Movement Disorders Center of Silicon Valley, co-lead investigator of the E3 program.
BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced positive topline results for the Phase 3 Essential3 program of ulixacaltamide in essential tremor (ET)
Make your voice heard loud and clear for Essential Tremor and
Turn today's dreams into tomorrow's realities!
Turn today's dreams into tomorrow's realities!
By joining forces, your generous gift to the Diann Shaddox Foundation is crucial for advancing vital research and developing data systems that bring us closer to a cure for Essential Tremor.
Together, we can bring hope to those who need it most.
DSF Millions of Faces of Essential Tremor
THESE ARE REAL PEOPLE LIVING EVERY DAY WITH ET.
|
|
There are many ways and resources to join the fight for ET.
Your unwavering support fuels our research. We are advancing toward a brighter future and new treatments.
Together, let's find a cure for ET.
Tell your ET StoriesYou are your best ET advocate. Tell your story to the world. For every person telling their story, millions are living in silence. >>> Learn More
|
Take Action for ETStand firm to support ET disease! Advocate passionately for the rights and needs of all patients, demanding new treatments and a cure. >>> Learn More
|
Ways to Give Donating to the Diann Shaddox Foundation funds ET research to develop treatments, understand causes, and find a cure. >>> Learn More
|
Why Give to the Diann Shaddox Foundation
|
The Foundation mobilizes resources and data for our ET Research which investigates ET disease's causes. Our mission is to uncover its mysteries and find a groundbreaking cure that transforms lives. We won't stop until we succeed.
|
|
Putting patients first involves addressing their physical, mental, and emotional needs. DSF advocates for recognition and change, aiming to improve their quality of life and health outcomes.
|
|
|
